NovoCure (NVCR) FCF Margin (2014 - 2026)
NovoCure (NVCR) posted quarterly FCF Margin of 0.66% for Q2 2026, up 1415.0% year-on-year from 0.04% in Q2 2025, and up 106.18% on a QoQ basis from 10.73% in Q1 2026.
NovoCure (NVCR) FCF Margin (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported FCF Margin for 13 consecutive years, with 0.66% the latest figure, recorded in Q2 2026.
- Quarterly FCF Margin rose 1415.0% year-over-year to 0.66% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.64% (up 912.0% YoY) and the FY2025 annual result came in at 11.55%, down 11.0% from the prior year.
- FCF Margin rose to 0.66% in Q2 2026 per NVCR's latest filing, from 10.73% in the prior quarter.
- Over the last five years, FCF Margin for NVCR reached as high as 12.76% in Q3 2022 and fell as low as 31.3% in Q1 2024.
- A 5-year average of 9.88% and a median of 9.74% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 3363 bps — and 2024, when it surged 2067 bps.
- Year by year, FCF Margin stood at 7.89% in 2022, then sank by 102 bps to 15.98% in 2023, then jumped by 52 bps to 7.68% in 2024, then sank by 71 bps to 13.13% in 2025, then soared by 105 bps to 0.66% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 0.66%, 10.73%, and 13.13% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | 0.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.66% |
| Mar 31, 2026 | -10.73% |
| Dec 31, 2025 | -13.13% |
| Sep 30, 2025 | 8.92% |
| Jun 30, 2025 | -13.49% |
| Mar 31, 2025 | -29.86% |
| Dec 31, 2024 | -7.68% |
| Sep 30, 2024 | -0.20% |
| Jun 30, 2024 | -8.76% |
| Mar 31, 2024 | -31.30% |
| Dec 31, 2023 | -15.98% |
| Sep 30, 2023 | -20.87% |
| Jun 30, 2023 | -23.54% |
| Mar 31, 2023 | -18.67% |
| Dec 31, 2022 | -7.89% |
| Sep 30, 2022 | 12.76% |
| Jun 30, 2022 | 8.26% |
| Mar 31, 2022 | -6.38% |
| Dec 31, 2021 | 0.10% |
| Sep 30, 2021 | 15.79% |